Viewing Study NCT05055232


Ignite Creation Date: 2025-12-24 @ 9:46 PM
Ignite Modification Date: 2026-01-02 @ 4:13 AM
Study NCT ID: NCT05055232
Status: COMPLETED
Last Update Posted: 2025-07-24
First Post: 2021-09-14
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Phase I Study of XZP-3621 in Chinese Patients With ALK or ROS1 Rearrangement Non-small Cell Lung Cancer
Sponsor: Xuanzhu Biopharmaceutical Co., Ltd.
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module